A Phase 1, 2-Stage, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 Following Single and Multiple Ascending Doses in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 31 Oct 2019
Price : $35 *
At a glance
- Drugs BBT 877 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; First in man
- Sponsors Bridge Biotherapeutics
- 22 Oct 2019 Planned End Date changed from 31 Jul 2019 to 31 Dec 2019.
- 22 Oct 2019 Planned primary completion date changed from 31 Jul 2019 to 30 Nov 2019.
- 29 Sep 2019 According to a Bridge Biotherapeutics media release, results from the study (n=80) were presented as a late breaking abstract at the European Respiratory Society International Congress 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History